[go: up one dir, main page]

AU2003223579A8 - Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease - Google Patents

Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease

Info

Publication number
AU2003223579A8
AU2003223579A8 AU2003223579A AU2003223579A AU2003223579A8 AU 2003223579 A8 AU2003223579 A8 AU 2003223579A8 AU 2003223579 A AU2003223579 A AU 2003223579A AU 2003223579 A AU2003223579 A AU 2003223579A AU 2003223579 A8 AU2003223579 A8 AU 2003223579A8
Authority
AU
Australia
Prior art keywords
cox
parkinson
inhibitors
disease
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003223579A
Other versions
AU2003223579A1 (en
Inventor
Timothy J Maziasz
Peter C Isakson
Diane T Stephenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2003223579A1 publication Critical patent/AU2003223579A1/en
Publication of AU2003223579A8 publication Critical patent/AU2003223579A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003223579A 2002-04-18 2003-04-14 Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease Abandoned AU2003223579A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37331102P 2002-04-18 2002-04-18
US60/373,311 2002-04-18
PCT/US2003/011269 WO2003088958A2 (en) 2002-04-18 2003-04-14 Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease

Publications (2)

Publication Number Publication Date
AU2003223579A1 AU2003223579A1 (en) 2003-11-03
AU2003223579A8 true AU2003223579A8 (en) 2003-11-03

Family

ID=29251013

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003223579A Abandoned AU2003223579A1 (en) 2002-04-18 2003-04-14 Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease

Country Status (8)

Country Link
US (1) US20040034083A1 (en)
EP (1) EP1494664A2 (en)
JP (1) JP2005528403A (en)
AU (1) AU2003223579A1 (en)
BR (1) BR0309259A (en)
CA (1) CA2481934A1 (en)
MX (1) MXPA04009352A (en)
WO (1) WO2003088958A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (en) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation
DE10041478A1 (en) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh New pharmaceutical composition
DE10041479A1 (en) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh New pharmaceutical composition for the administration of N-0923
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (en) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
DE60334406D1 (en) * 2002-12-23 2010-11-11 Merck Frosst Company PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE TREATMENT OF MORBUS PARKINSON
DE10261696A1 (en) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Device for the transdermal administration of rotigotine base
DE10315572A1 (en) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituted pyrazoles
DE10315571A1 (en) 2003-04-05 2004-10-14 Merck Patent Gmbh pyrazole
DE10315569A1 (en) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituted pyrazole compounds
DE10315573A1 (en) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituted pyrazoles
DE10334188B4 (en) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Use of rotigotine to treat depression
DE10334187A1 (en) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituted 2-aminotetralins for the treatment of depression
ATE380027T1 (en) 2003-09-09 2007-12-15 Fumapharm Ag USE OF FUMARIC ACID DERIVATIVES FOR THE TREATMENT OF HEART FAILURE AND ASTHMA
DE10359528A1 (en) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S) -2-N-propylamino-5-hydroxytetralin as a D3 agonist therapeutic
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (en) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Use of substituted 2-aminotetralins for the preventive treatment of Parkinson's disease
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (en) 2004-03-24 2006-07-06 Schwarz Pharma Ag Use of rotigotine for the treatment and prevention of Parkinson-Plus syndrome
WO2006071184A1 (en) * 2004-12-28 2006-07-06 Astrazeneca Ab Aryl sulphonamide modulators
TWI392670B (en) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
DK2215072T3 (en) * 2007-11-28 2015-09-14 Ucb Pharma Gmbh Polymorphic form of rotigotine
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
CN102048717B (en) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 Stable rasagiline composition
EA025584B1 (en) 2009-12-22 2017-01-30 ЮСиБи ФАРМА ГМБХ Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US5476944A (en) * 1991-11-18 1995-12-19 G. D. Searle & Co. Derivatives of cyclic phenolic thioethers
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
ATE233245T1 (en) * 1993-11-30 2003-03-15 Searle & Co SUBSTITUTED PYRAZOLYL-BENZENESULFONAMIDES AND THEIR USE AS CYCLOOXYGENASEII INHIBITORS
IS4233A (en) * 1993-12-22 1995-06-23 Astra Aktiebolag Misguided ring-related compounds
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
GB9514518D0 (en) * 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
NZ331542A (en) * 1996-04-12 1999-07-29 Searle & Co Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors and salts thereof that are useful in treating inflammation and inflammation-related disorders
WO1997046548A1 (en) * 1996-06-07 1997-12-11 The Procter & Gamble Company Dihydrobenzopyran and related compounds useful as anti-inflammatory agents
US6005000A (en) * 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
SE9701304D0 (en) * 1997-04-09 1997-04-09 Astra Pharma Prod Compounds
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
ZA985765B (en) * 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA57107C2 (en) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Treatment of conduct disorders
UA56257C2 (en) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Method for treating oppositional defiant disorder
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
JP2002517486A (en) * 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド inhibitors of p38
US6277878B1 (en) * 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents
AU764875B2 (en) * 1998-11-12 2003-09-04 Merck & Co., Inc. Combination of a GABA-A alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin
MXPA00006605A (en) * 1999-07-02 2004-12-09 Pfizer Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents.
DE60004001T2 (en) * 1999-12-03 2004-04-15 Pfizer Products Inc., Groton Acetylene derivatives for use as an analgesic or anti-inflammatory
US6306842B1 (en) * 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
GB0019006D0 (en) * 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
WO2002078625A2 (en) * 2001-03-28 2002-10-10 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
DE60332433D1 (en) * 2002-03-15 2010-06-17 Vertex Pharma AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
US7179826B2 (en) * 2002-03-15 2007-02-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases

Also Published As

Publication number Publication date
WO2003088958A2 (en) 2003-10-30
BR0309259A (en) 2005-02-09
WO2003088958A3 (en) 2004-08-19
AU2003223579A1 (en) 2003-11-03
EP1494664A2 (en) 2005-01-12
CA2481934A1 (en) 2003-10-30
MXPA04009352A (en) 2005-01-25
US20040034083A1 (en) 2004-02-19
JP2005528403A (en) 2005-09-22

Similar Documents

Publication Publication Date Title
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
EP1549614A4 (en) Vasculostatic agents and methods of use thereof
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
EP1571968A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1589933A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1578996A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1572091A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1553912A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1575571A4 (en) Compositions and methods for the diagnosis and treatment of tumor
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
IL164647A0 (en) Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease
AU2003268295A8 (en) "diagnosis and treatment of infertility"
HUP0303306A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
AU2003248893A8 (en) Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias
EP1539100A4 (en) Composition and methods for the treatment of skin disorders
AU2003279800A8 (en) Sulfatases and methods of use thereof
EP1684795A4 (en) Methods and agents for the treatment of cancer
AU2002339673A1 (en) Agonists and antagonists of ryzn for the treatment of metabolic disorders
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
AU2003294697A8 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
AU2003260515A8 (en) Derivatives of 4-4'-bipyridyl-2-2'-bisoxazoles and 4-4'-bipyridyl-2-2'-bistiazoles as antineoplasic agents
AU2002339680A1 (en) Agonists and antagonists of bromix for the treatment of metabolic disorders
AU2002303430A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1494709A4 (en) Compositions and methods for the diagnosis and treatment of tumor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase